Adalvo is delighted to announce the successful DCP closure for Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. We believe we are the first company to complete a DCP for a sublingual tablet.
Our niche peptide product has been developed based on the reference brand Minirin Melt from Ferring which is indicated for the treatment of diabetes insipidus, primary nocturnal enuresis and nocturia. The brand sold $125mio globally in 2021, according to IQVIA.
Adalvo is one of the very few companies working on this complex niche peptide product which has a very low bioavailability and highlights Adalvo's robust R&D strengths and capabilities, demonstrating our ability to continuously offer highly differentiated, value-added niche products to our partners